Form 4: BIOVIE Director Granted 420,500 Stock Options

BIOVIE Inc. Director James Paul Lang was granted 420,500 stock options with an exercise price of $1.31, vesting over several years.

Summary

• James Paul Lang, a Director of BIOVIE INC. (BIVI), was granted a total of 420,500 stock options.
• The options have an exercise price of $1.31 per share.
• The transaction date for these grants was January 5, 2026.
• The options are set to expire on January 5, 2031.
• One grant of 90,000 options vests in four equal installments on February 10, 2026, May 11, 2026, August 11, 2026, and the earlier of November 11, 2026, and the date of the registrant's 2026 annual shareholders' meeting.
• Another grant of 330,500 options had 75% vested on January 5, 2026, with the remaining portion vesting in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of an insider transaction (stock option grant) and does not contain information that would significantly alter the company's fundamental outlook or performance. It is a neutral event from a sentiment perspective.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance of BIOVIE Inc., potentially incentivizing value creation for shareholders.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction, focusing solely on an insider transaction.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry, as well as other sectors, to incentivize executive and board member performance and align their interests with long-term shareholder value. This is a standard compensation mechanism.

Comparison to Industry Standards

• Granting stock options to directors is a widely accepted compensation practice across various industries, including biotechnology, to attract and retain talent and align interests with shareholders.
• The vesting schedules, which extend over several years, are typical for equity compensation, designed to encourage long-term commitment and performance rather than short-term gains.

Related Party Transactions

• The grant of stock options to James Paul Lang, a Director of BIOVIE INC., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also improved alignment of the director's interests with shareholder value creation.
• Director (James Paul Lang): Increased personal stake in the company's success, providing a long-term incentive for performance.

Next Steps

• The vesting of the 90,000 options will occur in installments on February 10, 2026, May 11, 2026, August 11, 2026, and the earlier of November 11, 2026, and the 2026 annual shareholders' meeting.
• The remaining 25% of the 330,500 options will vest in equal installments on January 5, 2027, January 5, 2028, and January 5, 2029.

Key Dates

Keywords

BIOVIE, BIVI, stock options, insider transaction, Form 4, director compensation, equity grant